Monoclonal antibodies for immunological disorders: a review of recent patents

Bibliography

• KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256(5517):495–497.
   PubMed Web of Science ®Google Scholar
• TAYLOR PC, WILLIAMS RO, FELDMANN M: Tumour necrosis factor-a as a therapeutic target for immune-mediated inflammatory diseases. Curr. Opin. Biotechnol (2004) 15(6):557–563.
   PubMedGoogle Scholar
• FELDMANN M, MAINI RN: Anti-TNF-a therapy of rheumatoid arthritis: what have we learned? Ann. Rev. Immunol. (2001). 19:163–196.
   Google Scholar
• ANDREAKOS ET, FOXWELL BM, BRENNAN FM, MAINI RN, FELDMANN M: Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev. (2002) 13(4-5):299–313.
   PubMed Web of Science ®Google Scholar
• ANDREAKOS E: Targeting cytokines in autoimmunity: new approaches, new promise. Expert Opin. Biol. Ther. (2003) 3(3):435–447.
   PubMed Web of Science ®Google Scholar
• PFEFFER K: Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. (2003) 14(3-4):185–191.
   PubMed Web of Science ®Google Scholar
• QUEZADA SA, JARVINEN LZ, LIND EF, NOELLE RJ: CD40/CD154 interactions at the interface of tolerance and immunity. Ann. Rev. Immunol (2004) 22:307–328.
   PubMed Web of Science ®Google Scholar
• BRADDOCK M, QUINN A, CANVIN J: Therapeutic potential of targeting IL-1 and IL-18 in inflammation. Expert Opin. Biol Ther. (2004) 4(6):847–860.
   PubMed Web of Science ®Google Scholar
• DREVLOW BE, LOWS R, HAAG MA et al.: Recombinant human interleukin-1 receptor Type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. (1996) 39(2):257–265.
   PubMed Web of Science ®Google Scholar
• BRESNIHAN B, ALVARO-GRACIA JM, COBBY M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. (1998) 41(12):2196–2204.
   PubMed Web of Science ®Google Scholar
• JIANG Y, GENANT HK, WATT I et ell.: A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. (2000) 43 (5):1001–1009.
   Google Scholar
• COHEN S, HURD E, CUSH J et al.: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46(3):614–624.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB, FORTIN E, SCHIFFMAN R et al.: Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a Phase I/II clinical trial. Proc. Natl. Acad. Sci. USA (1999) 96(13):7462–7466.
   PubMed Web of Science ®Google Scholar
• WALDMANN T, TAGAYA Y, BAMFORD R: Interleukin-2, interleukin-15, and their receptors. Int. Rev. Immunol(1998) 16(3-4):205–226.
   PubMedGoogle Scholar
• WENDLING D, RACADOT E, WIJDENES J: Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody./ Rheumatol. (1993) 20(2):259–262.
   PubMedGoogle Scholar
• YOSHIZAKI K, NISHIMOTO N, MIHARA M, KISHIMOTO T: Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin. Immunopathol. (1998) 20(1-2):247–259.
   PubMed Web of Science ®Google Scholar
• MOSER B, WILLIMANN K: Chemokines: role in inflammation and immune surveillance. Ann. Rheum. Dis. (2004). 63\(Supp1.2):ii84-ii89.
   Google Scholar
• ZOLLER M: Costimulatory molecules and their ligands as therapeutic targets in autoimmune disease. Eur. J. DermatoL (2001) 11(4):335–342.
   PubMedGoogle Scholar
• DEDRICK RL, BODARY S, GAROVOY MR: Adhesion molecules as therapeutic targets for autoimmune diseases and transplant rejection. Expert Opin. Biol. Ther. (2003) 3(1):85–95.
   PubMed Web of Science ®Google Scholar
• ABRAMS JR, LEBWOHL MG, GUZZO CA et al.: CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. j Clin. Invest. (1999) 103(9):1243–1252.
   PubMed Web of Science ®Google Scholar
• ELLIS CN, KRUEGER GG: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J. Med. (2001) 345(4):248–255.
   PubMed Web of Science ®Google Scholar
• TUBRIDY N et al.: The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology (1999) 53(3):466–472.
   PubMed Web of Science ®Google Scholar
• ELICES MJ: Natalizumab. Elan/Biogen. Curr. Opin. Investig: Drugs. (2003). 4(11):1354–1362.
   PubMedGoogle Scholar
• GHOSH S, GOLDIN E, GORDON FH et al.: Natalizumab for active Crohn's disease. N Engl J Med. (2003) 348(1):24–32.
   PubMed Web of Science ®Google Scholar
• KIRKHAM BW, THIEN F, FELTON BK et al: Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. Rheumatol (1992) 19 (9):1348–1352.
   Google Scholar
• OLSEN NJ, BROOKS RH, CUSH JJ et al: A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Arthritis Rheum. (1996) 39(7):1102–1108.
   PubMedGoogle Scholar
• ISAACS JD, MANNA VK, RAPSON N et al: C.AMPATH-1H in rheumatoid arthritis - an intravenous dose-ranging study. Br. J. Rheumatol (1996) 35(3):231–240.
   Google Scholar
• CHOY EH, CHIKANZA IC, KINGSLEY GH et aL: Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand. j Immunol (1992) 36(2):291–298.
   PubMedGoogle Scholar
• CHOY EH, CONNOLLY DJ, RAPSON N et al: Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology (2000) 39(10):1139–1146.
   PubMedGoogle Scholar
• VEALE DJ, REECE RJ, PARSONS W et al: Intra-articular primatised anti-CD4: efficacy in resistant rheumatoid knees. A study of combined arthroscopy, magnetic resonance imaging, and histology. Ann. Rheum. Dis. (1999) 58(6):342–349.
   Google Scholar
• SHAN D, LEDBETTER JA, PRESS OW: Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. (2000):673–683.
   PubMedGoogle Scholar
• ANDERSON DR, GRILLO-LOPEZ A, VARNS C, CHAMBERS KS, HANNA N: Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem. Soc. Trans. (1997):705–708.
   PubMedGoogle Scholar
• EDWARDS JC, SZCZEPANSKI L, SZECHINSKI J et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J. Med. (2004) 350(25):2572–2581.
   PubMed Web of Science ®Google Scholar